Provided by Tiger Trade Technology Pte. Ltd.

4D Molecular Therapeutics

15.83
-0.2700-1.68%
Post-market: 15.43-0.4000-2.53%19:30 EDT
Volume:921.17K
Turnover:14.68M
Market Cap:874.52M
PE:-5.74
High:16.91
Open:16.32
Low:15.33
Close:16.10
52wk High:16.93
52wk Low:5.97
Shares:55.24M
Float Shares:42.02M
Volume Ratio:0.45
T/O Rate:2.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7580
EPS(LYR):-2.4200
ROE:-43.25%
ROA:-25.09%
PB:2.15
PE(LYR):-6.54

Loading ...

4D Molecular price target lowered to $23 from $45 at Evercore ISI

TIPRANKS
·
Apr 13

4D Molecular Therapeutics Consolidates Financial Leadership Under New Role

TIPRANKS
·
Mar 31

4D Molecular Therapeutics names CFO Kristian Humer principal accounting officer

Reuters
·
Mar 31

4D Molecular Therapeutics Coverage Assumed by Jefferies at Buy

Dow Jones
·
Mar 31

U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan

Reuters
·
Mar 30

4D Molecular Therapeutics VP Finance and Controller Ashoo Gupta disposes of USD 3,356 in common shares

Reuters
·
Mar 25

Reimbursement and Pricing Pressures Threaten Commercial Outlook for 4D Molecular Therapeutics’ Gene Therapies

TIPRANKS
·
Mar 20

4D Molecular Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
Mar 19

4D Molecular Therapeutics (FDMT) Receives a Hold from Cantor Fitzgerald

TIPRANKS
·
Mar 19

RBC Raises Price Target on 4D Molecular Therapeutics to $35 From $32, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Mar 19

Chardan Capital Remains a Buy on 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Mar 19

4D Molecular Therapeutics publishes corporate presentation on 4D-150 retinal gene therapy program

Reuters
·
Mar 19

4D Molecular Therapeutics Q4 EPS $0.43 Beats $(0.82) Estimate, Sales $85.090M Beat $21.817M Estimate

Benzinga Earnings
·
Mar 19

4D Molecular Therapeutics FY 2025 R&D expenses rise 39% to USD 196 million, net loss narrows 13% to USD 140 million

Reuters
·
Mar 19

Press Release: 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Dow Jones
·
Mar 19

4D Molecular Therapeutics Inc expected to post a loss of 76 cents a share - Earnings Preview

Reuters
·
Feb 24